Financial Data and Key Metrics Changes - Trip.com Group reported a net revenue of RMB 18.3 billion for Q3 2025, representing a 16% increase year-over-year and a 24% increase quarter-over-quarter, driven by robust travel demand [17] - Accommodation reservation revenue increased by 18% year-over-year to RMB 8.0 billion, and transportation ticketing revenue rose by 12% year-over-year to RMB 6.3 billion [17] - Adjusted EBITDA for Q3 was RMB 6.3 billion, compared to RMB 5.7 billion in the same period last year [19] Business Line Data and Key Metrics Changes - Outbound hotel and air bookings grew by close to 20% year-over-year, reaching about 140% of 2019 volumes [6] - Package tour revenue increased by 3% year-over-year to RMB 1.6 billion, with a significant 49% increase quarter-over-quarter [18] - Corporate travel revenue rose by 15% year-over-year to RMB 756 million, driven by more companies adopting managed corporate travel services [18] Market Data and Key Metrics Changes - Inbound travel bookings on the platform grew by over 100% year-over-year, reflecting robust international demand [9] - The Asia-Pacific region remains the largest source of inbound travelers, with Europe and the U.S. also seeing strong growth [9] - International bookings increased by around 60% year-over-year, with the Asia-Pacific region contributing over 50% to this growth [10] Company Strategy and Development Direction - The company aims to leverage AI innovation to enhance travel experiences and improve service delivery [5] - Trip.com Group is focusing on expanding its international presence, particularly in the Asia-Pacific region, while also enhancing its offerings for inbound travelers [48] - The company is committed to nurturing the broader travel ecosystem and supporting local economic development through strategic partnerships [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth of the travel industry, emphasizing the importance of enhancing services and empowering the broader ecosystem [16] - The company remains optimistic about the future of travel, particularly with the growing demand for diverse and immersive experiences [5] - Management noted that challenges in the market present opportunities to strengthen the company's foundation and expand its market share [38] Other Important Information - The company launched a free layover experience for travelers at Hong Kong International Airport, enhancing its offerings for international visitors [10] - The number of Old Friends Club members increased by over 70%, indicating a growing focus on catering to affluent and active seniors [11] Q&A Session Summary Question: Insights on AI's role in Trip.com's strategy - Management highlighted AI as a central pillar of the company's strategy, with significant growth in the use of AI-driven tools and a focus on enhancing user experiences [24] Question: Consumer behavior trends during national holidays - Management noted strong trends in long stays and long-distance travel during the national holiday, with outbound hotel and air bookings jumping over 30% year-over-year [28] Question: Recent trends in hotel and air ticket prices - Hotel and air ticket prices have shown a narrowing decline, with domestic hotel prices trending higher during the Golden Week [33] Question: Insights on consumer sentiment and outlook for 2026 - Management observed strong travel demand and a desire for immersive experiences, with a focus on enhancing products and services for evolving traveler needs [37] Question: Impact of competition in the China market - Management emphasized the importance of technology and customer service in maintaining a competitive edge, while also investing in improving efficiency across the industry [42] Question: Updates on international performance - International bookings increased by around 60% year-over-year, with a strong focus on the Asia-Pacific region driving growth [48] Question: Inbound travel growth catalysts - Management cited positive feedback from inbound customers regarding safety and hospitality, along with the convenience of visa policies as key growth drivers [53] Question: Marketing strategy and future plans - The marketing strategy delivered solid results, with plans to continue executing signature campaigns while adapting to emerging market trends [59] Question: Dynamics in the global market and competition - Management noted the potential for growth in the Asia-Pacific market and emphasized the importance of localized products and exceptional customer service [62] Question: Long-term positioning of destination services - Management indicated that the destination service business is expected to grow significantly, focusing on enhancing user experience and customer loyalty [68] Question: Outlook for operating expenses - Management plans to manage investments with discipline, adjusting spending based on market maturity and maintaining high standards for new hires [72] Question: Margin expansion outlook - Management stated it is too early to provide specific margin outlooks but emphasized ongoing improvements in operating efficiency as a key driver for future margins [76]

Financial Data and Key Metrics Changes - The company reported gross revenues of BRL 4.9 billion, representing a 9% growth year over year and a 6% growth quarter over quarter [19] - Net income reached BRL 1.3 billion, a 12% growth year over year and a 1% increase quarter over quarter [23] - The return on equity (ROE) was 23%, flat year over year, while the capital ratio stood at 21.2%, an increase of 180 basis points quarter over quarter [7][24] Business Line Data and Key Metrics Changes - Retail revenues reached BRL 3.7 billion, representing 6% growth year over year and 4% growth quarter over quarter [19] - Corporate and industry services achieved a record performance of BRL 729 million, with 32% growth year over year and 33% growth quarter over quarter [21] - Life insurance retail premium posted a 25% growth year over year, while retirement plans client assets grew 15% year over year, reaching BRL 90 billion [14] Market Data and Key Metrics Changes - The company reported BRL 20 billion in retail net new money and BRL 9 billion in corporate and institutional, totaling BRL 5 billion lower than last year but three times higher than last quarter [8] - The company maintained a 10% market share in capital markets distribution, with a robust pipeline of fixed income offerings [15] Company Strategy and Development Direction - The company aims to become the leader in investments in Brazil by enhancing client service and introducing new products, including a new app and credit card offerings [3][10] - The strategy includes democratizing access to high-quality wealth planning services, previously reserved for high-net-worth clients [10][12] - The company is focused on improving its investment platform and enhancing client experience through advisor initiatives [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2025 but emphasized commitment to evolving the business for growth and profitability [4] - The outlook for the wholesale banking segment remains positive, with expectations for continued strong performance in Q4 [31] - Management indicated that while achieving the 10% revenue growth target for 2025 may be challenging, they remain optimistic about future growth [82] Other Important Information - The company repurchased BRL 2 billion in shares in 2025, with a new BRL 1 billion buyback program announced [24] - The company plans to pay a dividend of BRL 500 million in 2025, representing a 50% payout ratio based on net income [24] Q&A Session Summary Question: Expectations for wholesale business performance in Q4 - Management expects good performance in the wholesale banking segment for Q4, with a strong second half of the year compared to the first half [31][33] Question: Details on the strategy to increase the warehousing book - The strategy involves holding high-quality assets and increasing the warehouse book to sell to retail clients in the following year [33] Question: Clarification on corporate revenues and hedging strategy - Corporate revenues are tied to DCM activity, with hedging solutions being a significant driver [39] Question: Insights on fixed income revenue contraction despite AUC growth - The contraction in fixed income revenues is attributed to a shift in the mix towards lower take rates and shorter durations [46] Question: Impact of new hires on advisor numbers - The decrease in the number of advisors is due to the conversion of IFAs into employees and a focus on hiring higher-quality advisors [52] Question: Explanation for the reduction in financial expenses - The reduction in financial expenses is linked to a geographic shift in debt management, with cheaper bank debt replacing corporate debt [54] Question: Future guidance on EBIT margin - Management believes achieving the EBIT margin guidance is still possible, but it may take until the end of next year to realize [62]

Financial Data and Key Metrics Changes - The company achieved a positive adjusted EBITDA of nearly $500,000 for the first time in its history, marking a significant milestone [3] - Cash generated from operations was over $250,000, indicating a positive cash flow transformation [3] - Q3 revenue reached $6.8 million, a 30% increase year-over-year and a 20% increase quarter-over-quarter [7] - Adjusted EBITDA improved to $469,000 compared to $100,000 a year ago and a loss of $78,000 in the previous quarter [17] - Cash from operations swung positively to $285,000 from a cash burn of $148,000 in the previous quarter, representing a $433,000 improvement [17] Business Line Data and Key Metrics Changes - The Pathology Services Division generated $6 million in Q3, a 20% increase from $5 million in Q2, driven by new customer acquisitions [8] - Gross margin for the Pathology Services Division improved from 43% to 46% due to efficient operations [17] - The Products Division saw a 16% quarter-over-quarter growth, increasing from approximately $620,000 in Q2 to $720,000 in Q3 [10] - Overall gross margins improved slightly from 43% to 44%, with expectations for continued upward trends as both divisions grow [11] Market Data and Key Metrics Changes - The company has seen a tripling of its share price since the beginning of 2023, reflecting market confidence in its financial performance [5] - The company is positioned to leverage its distributor network for scalable growth, indicating a shift in market strategy [11] Company Strategy and Development Direction - The company is transitioning from a defensive to an offensive strategy, focusing on reinvesting cash generated into growth initiatives [3][5] - Future priorities include driving double-digit growth in both divisions, expanding margins, and increasing liquidity and share price appreciation [19] - The company aims to achieve gross margins exceeding 50% by mid-2026 as both divisions build revenues on existing infrastructure [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's self-sustaining business model, indicating no need for outside capital to cover operational costs [18] - The company is optimistic about continued growth and market opportunities as it enhances its operational and financial success [19] - Management highlighted the importance of their mission in improving patient care, emphasizing that growth translates into better treatment outcomes [19] Other Important Information - The company is nearing the completion of its full repayment of Change Healthcare, which will free up cash generated from operations starting in Q1 2026 [18] - The company has made strategic investments in lab space and technical support to enhance operational efficiency and customer onboarding [12][15] Q&A Session Summary - No specific questions or answers were provided in the content, indicating that the conference call concluded without a Q&A segment [21]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258, with a 34-location increase, and the annual customer count expanded to approximately 6.5 million [2] - Financial performance showed signs of recovery, with sales previously affected by restructuring and franchise fees, but now supported by an increase in point-related revenues [3] - Operating income and net income improved due to a decline in racing-related costs, including share-based compensation expenses [3] Business Line Data and Key Metrics Changes - The average revenue per customer visit is recovering due to pricing and promotion initiatives, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D and expanding unique service offerings through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The financial impact of the new BREATH initiative in Thailand is expected to be minimal in the near term, with plans to expand into other Asian countries after proof of concept [10] Company Strategy and Development Direction - The company aims to strengthen its overall competitiveness and achieve sustainable growth through strategic acquisitions and partnerships, particularly in the aesthetic medical field [5][20] - The M&A strategy is divided into domestic and global perspectives, focusing on clinic field acquisitions in Japan and exploring investment opportunities in the US market [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining the positive momentum observed in Q3, with expectations for stable financial performance in Q4 and the following year [11][22] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [22][26] Other Important Information - The company is working on improving share liquidity through new share issuance and potential share buybacks, acknowledging that the current share price is too low [6][24] - Dividend payments are being considered as a way to attract new investors, although the company prioritizes capital allocation towards strategic initiatives [25] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a franchise fee division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with financial performance expected to continue improving [8] Question: Could you elaborate on the balance sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [9] Question: What is the expected impact of the new BREATH initiative in Thailand? - The near-term financial impact will be minimal as the company conducts proof of concept for laser treatments, with plans for future expansion into other Asian markets [10] Question: What is the expectation for organic growth going forward? - The company anticipates maintaining the positive momentum from Q3, with expectations for stable financial performance in the upcoming quarters [11] Question: Can you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through enhanced sales of Waku products at SBC clinics and joint development of pharmaceutical and medical devices [12][15] Question: Can you comment on the latest status of US business development efforts? - The company is in the phase of understanding the US market and seeking strong partners to leverage its strengths from Japan, with cautious plans for future clinic development [17][18] Question: What are the expectations for M&A going forward? - The M&A strategy will focus on domestic clinic acquisitions and exploring investment opportunities in the global market, particularly in the US [20] Question: How do you plan to improve the liquidity situation? - Plans include increasing free float through new share issuance and potential share buybacks, acknowledging the current low share price [24] Question: Do you think about the dividend going forward? - Dividend payments are considered to attract new investors, but the company prioritizes capital allocation towards growth opportunities [25] Question: Do you have any plan to disclose financial guidance going forward? - The company is considering providing financial guidance in the near future [26]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258 clinics, with an annual customer base expanding to approximately 6.5 million [2][3] - Financial performance showed signs of recovery, with operating income and net income benefiting from a decline in racing-related costs and an increase in point-related revenues [3][4] Business Line Data and Key Metrics Changes - The average revenue per customer visit is recovering due to pricing and promotion strategies, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D capabilities through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The company is exploring proof of concept (POC) initiatives in Thailand, with plans to expand into other Asian markets like Malaysia and Indonesia [11] Company Strategy and Development Direction - The company aims to strengthen its overall competitiveness and achieve sustainable growth through strategic partnerships and acquisitions, particularly in the aesthetic medical and clinical industries [20] - The U.S. market entry strategy involves forming strong partnerships and leveraging learnings from the Japanese market, while being cautious about direct replication of the business model [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining positive momentum in financial performance, expecting stable growth in Q4 and the following year [12][21] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [21][25] Other Important Information - The company is working on improving liquidity through measures such as new share issuance and potential share buybacks, acknowledging the current low share price [6][23] - Dividend payments are being considered as a way to attract new investors, although the focus remains on capital allocation for strategic initiatives [24] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a Franchise Fee Division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with expectations of continued positive trends [9] Question: Could you elaborate on the Balance Sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [10] Question: What is your expectation for organic growth going forward for both breadth and revenue? - The company expects to maintain positive momentum seen in Q3, with stable financial performance anticipated in Q4 and next year [12] Question: Could you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through enhanced sales of Waku products at SBC clinics and joint development of pharmaceutical and medical devices [15][16] Question: Can you comment on the latest status of your U.S. business development efforts? - The company is in a phase of understanding the U.S. market and seeking strong partners, with plans for future growth and expansion once comfortable [17][18] Question: What do you mean by more stable financial performance in Q4 and 2026? - Management confirmed expectations for revenue growth but could not provide specific numbers at this time [21] Question: How do you think about improving the liquidity situation? - The company is considering new share issues and share buybacks to increase free float and address low share prices [23] Question: Do you have any plan to disclose financial guidance or performance guidance going forward? - The company is actively considering providing financial guidance in the near future [25]

Financial Data and Key Metrics Changes - The company reported total client assets of BRL 1.9 trillion, reflecting a 16% year-over-year growth [4] - Gross revenues reached BRL 4.9 billion, representing a 9% growth year over year [19] - Earnings Before Tax (EBT) increased by 10% year over year to BRL 1.3 billion [23] - The company achieved a Return on Equity (ROE) of 23%, remaining flat year over year [7] - Diluted Earnings Per Share (EPS) grew by 13% year over year, reaching BRL 2.47 [25] Business Line Data and Key Metrics Changes - Retail revenues amounted to BRL 3.7 billion, showing a 6% growth year over year [19] - Corporate and industry services achieved a record revenue of BRL 729 million, with a 32% year-over-year growth [21] - Life insurance retail premiums grew by 25% year over year [14] - Credit revenues posted an 11% growth year over year, reaching BRL 83 million in Net Interest Income (NII) [14] Market Data and Key Metrics Changes - The company reported BRL 20 billion in retail net new money, which was three times higher than the previous quarter but BRL 5 billion lower than last year [8] - The company maintained a 10% market share in capital markets distribution [15] - The wholesale banking segment showed strong performance, with expectations for continued growth in the fourth quarter [31] Company Strategy and Development Direction - The company aims to become the leader in investments in Brazil by enhancing client service and introducing new products [3] - A focus on high-quality wealth planning services for clients with varying asset levels is part of the strategy [10] - The company is transitioning to a fee-based model, which currently accounts for 21% of total retail Assets Under Custody (AUC) [11] - The company is committed to investing in technology and expanding its sales force to enhance client experience [22] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the challenges faced in 2025 but emphasized the commitment to evolving the business for growth and profitability [4] - The management expressed confidence in achieving a target of around BRL 20 billion in retail net new money per quarter [8] - The company anticipates a volatile market in 2026, which may present opportunities for growth [70] Other Important Information - The company repurchased BRL 2 billion in shares in 2025, with a new buyback program of BRL 1 billion announced [24] - A dividend of BRL 500 million is planned for 2025, representing a 50% payout ratio based on net income [24] Q&A Session Summary Question: Expectations for wholesale business performance in Q4 - Management expects continued strong performance in the wholesale banking segment for Q4, with a focus on high-quality assets [31][33] Question: Clarification on corporate revenues and hedging strategy - Corporate revenues are tied to debt issuance and hedging solutions, with expectations for continued strength due to low credit spreads [76] Question: Insights on retail revenue growth and fixed income performance - Fixed income revenues contracted due to a shift in product mix towards lower take rates, while retail revenues grew overall [43][46] Question: Impact of new hires on advisor numbers - The company is hiring more internal advisors while converting some independent financial advisors (IFAs) to employees, focusing on quality over quantity [52] Question: Financial expenses and borrowing reductions - The reduction in financial expenses is attributed to a geographic shift in debt management, resulting in lower overall costs [53] Question: Guidance on EBT margin and revenue expectations - Management remains optimistic about achieving medium-term guidance for EBT margins, despite potential shortfalls in revenue growth [84]

Financial Data and Key Metrics Changes - The company achieved a positive adjusted EBITDA of nearly $500,000 for the first time in its history, marking a significant financial milestone [3] - Cash generated from operations was over $250,000, indicating a shift towards financial independence [3] - Q3 revenue reached $6.8 million, a 30% increase year-over-year and a 20% increase quarter-over-quarter [7] - Adjusted EBITDA improved to $469,000 compared to $100,000 a year ago and a loss of $78,000 in the previous quarter [17] - Cash from operations showed a positive swing of $433,000, moving from a cash burn of $148,000 in Q2 to a cash generation of $285,000 in Q3 [17] Business Line Data and Key Metrics Changes - The Pathology Services Division generated $6 million in Q3, a 20% increase from $5 million in Q2, driven by new customer acquisitions [8] - Gross margin for the Pathology Services Division improved from 43% to 46% due to efficient operations [17] - The Products Division saw a 16% quarter-over-quarter growth, increasing from approximately $620,000 in Q2 to $720,000 in Q3 [10] - Overall gross margins improved slightly from 43% to 44%, with expectations for continued upward trends as both divisions grow [11] Market Data and Key Metrics Changes - The company’s share price has tripled since the beginning of 2025, reflecting market confidence in its financial performance [5] - The company is experiencing a strong sales funnel with several new customers in trial phases, indicating potential for future growth [8] Company Strategy and Development Direction - The company is transitioning from a defensive to an offensive strategy, focusing on reinvesting cash generated into growth initiatives [3][5] - Plans include driving double-digit growth in both divisions, expanding margins, and increasing liquidity and share price appreciation [19] - The company aims to leverage its financial independence to explore strategic partnerships and innovative products [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company’s ability to grow organically without reliance on outside capital, marking a significant operational threshold [18] - The focus is on maintaining a culture of accountability, collaboration, and customer empathy to support sustained growth [9] - Future priorities include continued growth, margin expansion, and strategic reinvestment to enhance market position [19] Other Important Information - The company is nearing the completion of its full repayment of Change Healthcare, which will free up cash generated from operations starting in Q1 2026 [18] - The company has made strategic investments in lab space and technical support to enhance operational efficiency and customer onboarding [12][15] Q&A Session Summary - No specific questions or answers were provided in the content, indicating that the conference call concluded without a Q&A segment [21]

Financial Data and Key Metrics Changes - For Q3 2025, the company achieved a positive adjusted EBITDA of nearly $500,000 and generated over $250,000 in cash from operations, marking a significant financial milestone [3][15] - Revenue for Q3 reached $6.8 million, representing a 30% increase year-over-year and a 20% increase quarter-over-quarter [6] - Adjusted EBITDA improved to $469,000 compared to $100,000 a year ago and a loss of $78,000 in Q2 2025, indicating a swing of over $500,000 in just one quarter [15] - Cash generated from operations was $285,000, a positive cash swing of $433,000 compared to a cash burn of $148,000 in the previous quarter [15] Business Line Data and Key Metrics Changes - The Pathology Services Division reported revenue growth from $5 million in Q2 to $6 million in Q3, a 20% increase, driven by new customer acquisitions [7] - The Products Division experienced a 16% quarter-over-quarter growth, increasing from approximately $620,000 in Q2 to $720,000 in Q3, primarily due to increased utilization from existing customers and new product introductions [9][10] - Gross margins improved from 43% to 44% overall, with the Pathology Services Division increasing margins from 43% to 46% [10][15] Market Data and Key Metrics Changes - The company has seen a tripling of its share price since the beginning of 2023, reflecting market confidence in its financial performance and growth strategy [5] - The company is experiencing a strong sales funnel with several new customers in trial phases, indicating a robust market demand for its services [7] Company Strategy and Development Direction - The company is transitioning from a defensive to an offensive strategy, focusing on reinvesting cash generated from operations to accelerate growth [3][5] - Future priorities include driving double-digit growth in both divisions, expanding margins, and reinvesting cash into growth initiatives [17] - The company aims to achieve a gross margin exceeding 50% by mid-2026 as both divisions scale up [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's self-sustaining business model, stating that it will no longer depend on outside capital for operations [16] - The company anticipates that increased market capitalization will present new strategic opportunities for growth and partnerships [16] - Management emphasized the importance of their mission, linking financial success to improved patient care outcomes [17] Other Important Information - The company is nearing the completion of its full repayment of Change Healthcare, which will free up cash generated from operations starting in Q1 2026 [16] - The company has made strategic investments in lab space and technical support to enhance operational efficiency and customer onboarding [11][14] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financial Data and Key Metrics Changes - The company reported total client assets of BRL 1.9 trillion, reflecting a 16% year-over-year growth [4] - Gross revenues reached BRL 4.9 billion, representing a 9% growth year over year [5][18] - EBIT increased by 10% year over year to BRL 1.3 billion [5] - The return on equity (ROE) was 23%, remaining flat year over year [6] - Diluted EPS grew by 13% year over year, reaching BRL 2.47 per share [24] Business Line Data and Key Metrics Changes - Retail revenues amounted to BRL 3.7 billion, showing a 6% growth year over year [18] - Corporate and industry services achieved a record BRL 729 million in revenues, marking a 32% growth year over year [18] - Life insurance retail premiums grew by 25% year over year [13] - Credit revenues increased by 11% year over year, reaching BRL 83 million in net interest income [13] Market Data and Key Metrics Changes - Retail net new money was BRL 20 billion, a decrease of BRL 5 billion compared to the previous year but three times higher than the last quarter [7] - The company maintained a 10% market share in capital markets distribution [15] - The wholesale bank maintained a leadership position with a 17% market share [16] Company Strategy and Development Direction - The company aims to become the leader in investments in Brazil by enhancing client service and introducing new products [3][10] - A focus on high-quality wealth planning services for clients with varying asset levels is being emphasized [10] - The company is transitioning to a fee-based model, which currently accounts for 21% of total retail assets under custody [11] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the challenges faced in 2025 but expressed commitment to evolving the business for growth and profitability [4] - The company anticipates continued growth in retail net new money, targeting around BRL 20 billion per quarter [9] - Management highlighted the importance of maintaining a conservative risk profile despite strong performance in wholesale banking [25] Other Important Information - The company repurchased BRL 2 billion in shares in 2025, with a new buyback program of BRL 1 billion announced [23] - A dividend of BRL 500 million is planned for 2025, representing a 50% payout ratio based on net income [23] Q&A Session Summary Question: Expectations for wholesale business performance in Q4 - Management expects good performance in Q4, with stronger results anticipated compared to the first half of the year [26][27] Question: Details on the strategy to increase the warehousing book - The strategy involves holding high-quality assets and managing credit spread volatility effectively [27] Question: Clarification on corporate revenue increase - Corporate revenues are closely tied to debt issuance and hedging solutions, with strong performance expected to continue [30][44] Question: Insights on retail revenue growth despite fixed income contraction - The contraction in fixed income revenues is attributed to a shift in product mix and shorter durations affecting take rates [31][33] Question: Impact of workdays on revenues - Business days positively impacted floating and trading volumes, offsetting declines in equities and fixed income [49] Question: Use of AI in client advisory services - The company is leveraging AI to enhance advisor productivity and improve client service, particularly for lower-income clients [51]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258, with a 34-location increase, and the annual customer count expanded to approximately 6.5 million [2] - Financial performance showed signs of recovery, with sales previously affected by restructuring and franchise fee division, but now supported by an increase in point-related revenues [3][4] - The decline in racing-related costs, including share-based compensation expenses, contributed to improvements in both operating income and net income [3] Business Line Data and Key Metrics Changes - The average revenue per customer visit is showing signs of recovery due to pricing and promotion initiatives, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D and expanding service offerings through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The financial impact of the new BREATH initiative in Thailand is expected to be minimal in the near term as the company conducts proof of concept trials [10] Company Strategy and Development Direction - The company aims to strengthen its competitiveness and achieve sustainable growth through strategic acquisitions and partnerships, particularly in the aesthetic medical field [5][20] - The M&A strategy is divided into domestic and global perspectives, focusing on clinic acquisitions in Japan and exploring investments in the global market, especially in the US [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining the positive momentum observed in Q3 2025, with expectations for stable financial performance in Q4 and 2026 [11][22] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [22][26] Other Important Information - The company is working on improving liquidity by increasing free float shares and considering new share issuances and share buybacks [24] - Dividend payments are being considered as a way to attract new investors, although the company prioritizes capital allocation towards strategic initiatives [25] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a franchise fee division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with financial performance expected to continue improving [8] Question: Could you elaborate on the balance sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [9] Question: What is your expectation for organic growth going forward for both breadth and revenue? - The company expects to maintain the positive momentum seen in Q3, with more stable financial performance anticipated in Q4 and next year [11] Question: Can you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through strengthening sales of Waku products at SBC clinics and jointly developing pharmaceutical and medical devices [12][14] Question: Can you comment on the latest status of your US business development efforts? - The company is in the phase of understanding the US market and seeking strong partners to leverage its strengths from Japan [17] Question: What do you mean by more stable financial performance in Q4 and 2026? - Management confirmed expectations for a return to revenue growth but could not provide specific numbers at this time [22] Question: How do you think about improving the liquidity situation? - The company aims to increase free float shares and is considering share buybacks due to the current low share price [24] Question: Do you have any plan to disclose financial guidance or performance guidance going forward? - The company is actively considering providing financial guidance in the near future [26]